Matrix Laboratories Limited

Mylan Laboratories Limited

Chava Satyanarayana

Gorantla Seeta Ramanjaneyulu

Indukuri Venkata Sunil Kumar

Vellanki Siva Ram Prasad

Vasireddy Umamaheswara-Rao

Balusu Rajababu

The present invention provides novel crystalline forms of Nelfinavir mesylate, Form-A, Form-B, Form-C, Form-D and the process for their preparation without the use of any special equipment such as a spray drier, avoiding the use of highly flammable solvents such as ethers. The crystalline form can be tailored with the selection of the ante solvent and appropriate conditions for the process.

Crystalline forms of Nelfinavir mesylate

The present invention relates to a process for purification of novel polymorphic form of Gatifloxacin which comprises dissolving Gatifloxacin in about 15-50 volumes of methanol, removing insolubles if any, adding organic base to the solution, maintaining the solution at temperature of 30&#xb0; C. to 70&#xb0; C., for about 20 min to 4 hrs, followed by gradual cooling and maintaining the reaction mass to &#x2212;10 to 20&#xb0; C. for about 1-4 hrs, isolation and drying at temperature of about 45&#xb0; C. to 65&#xb0; C.

Crystalline forms of Gatifloxacin

The present invention relates to a new industrial feasible process for the preparation of Gabapentin Form-II via a novel intermediate Gabapentin hemisulphate hemihydrate with out forming Gabapentin Form-III by neutralizing the Gabapentin hemisulphate hemihydrate solution with a base at higher temperatures followed by cooling to yield Gabapentin Form II with sulphate ions less than 100 ppm with respect to Gabapentin.

Growing community of inventors

Secunderabad, India

Chava Satyanarayana